Skip to main content

Gasser Elizabeth Anne's Form 4 filing

Tandem Diabetes Care Inc (TNDM) · filed Nov 5, 2021

Accession no.
0001438133-21-000203
Filed
Nov 5, 2021
Trade date
Nov 3, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.05M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gasser Elizabeth AnneCIK 0001866283Officer (EVP, Chief Strategy Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 3, 2021Common StockMOption exerciseAcquired+15,936$89.54+$1,426,909.4417,154Direct
Nov 3, 2021Common StockMOption exerciseAcquired+4,874$82.34+$401,325.1622,028Direct
Nov 3, 2021Common StockSSaleDisposed−21,785$140.02F3−$3,050,335.7243Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 3, 2021Common StockMOption exerciseAcquired+15,936$89.54+$1,426,909.4422,311Direct
Nov 3, 2021Common StockMOption exerciseAcquired+4,874$82.34+$401,325.168,887Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $140.00 to $140.18. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)